Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
48 hedge funds and large institutions have $205M invested in Akero Therapeutics in 2019 Q2 according to their latest regulatory filings, with 48 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
39.46% more ownership
Funds ownership: 0% → 39.46% (+39%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VP
venBio Partners
San Francisco,
California
|
+$75M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$22.2M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$14.6M |
| 4 |
Janus Henderson Group
London,
|
+$14.4M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$12.3M |
Top Sellers
AKRO Hedge Fund Activity: Q2 2019 in Review
48 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q2 2019, worth a combined $205M.
Buyers outnumbered sellers: 48 funds opened new AKRO positions and 0 closed out — a net gain of 48 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was venBio Partners, opening a new position worth an estimated $75M.
- 48 institutional investors held Akero Therapeutics (AKRO) as of Q2 2019, up from 0 in Q1 2019.
- Funds reported $205M of Akero Therapeutics stock for Q2 2019.
- 48 funds opened new Akero Therapeutics positions in Q2 2019 and 0 closed out, a net change of +48 holders.
- The largest Akero Therapeutics buyer in Q2 2019 was venBio Partners, an estimated $75M added.
Based on aggregated 13F filings for Q2 2019.